Pivotal's Founder and Chairman Dr. George Jackowski receives Queen Elizabeth II Diamond Jubilee Medal

Woodbridge, Ontario (ots/PRNewswire) -

Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty
pharmaceutical company with a focus on Omega-3 therapies for
cardiovascular disease (CVD) and overall health, is pleased to
announce that Dr. George Jackowski, Founder, Chairman and Chief
Scientific Officer was awarded the Queen Elizabeth II Diamond Jubilee
Medal for his significant contribution to the Canadian Biotech and
Pharmaceutical Industries. Prime Minister Stephen Harper presented
the award to Dr. Jackowski on April 30, 2013 in the Prime Minster's
Parliament Hill Office.

"Pivotal congratulates Dr. Jackowski on his Diamond Jubilee
Medal," stated Mr. Eugene Bortoluzzi, Chief Executive Officer. "As
one of the pioneers of Canadian Biotech over the past thirty years,
his contribution has led to a significant improvement in the quality
of life and care for cardiac patients. Dr. Jackowski is responsible
for saving thousands of lives with the development of the rapid
format cardiac blood test, which remains the standard of care for
triaging patients presenting to the emergency room with chest pain."

Dr. Jackowski developed the first rapid format cardiac test over
twenty years ago, which is currently used worldwide in hospitals and
emergency rooms. The Cardiac Panel point of care test, commonly known
as the "cardiac enzymes", is used to diagnose individuals presenting
with chest pain to the emergency room. Dr. Jackowski's current
research focus on the treatment and prevention of cardiac risk
factors, resulted in the development of Pivotal's unique Omega-3
formulation, VASCAZEN(R), for the treatment of an Omega-3 dietary
deficiency in cardiovascular patients.

The Queen Elizabeth Diamond Jubilee Medal honours significant
contributions and achievements by Canadians. The commemorative medal
was created by the Government of Canada to mark the 2012 celebrations
of the 60th anniversary of Her Majesty Queen Elizabeth II's accession
to the Throne.

About Dr. George Jackowski

Dr. Jackowski has founded 12 biotechnology companies in his
career. Additionally, he has contributed to the creation of another
12 biotechnology companies, and the creation of over 1,000 high tech
jobs in the biotech sector. Dr. Jackowski is currently the Chairman
and Chief Scientific Officer of Pivotal Therapeutics Inc. Dr.
Jackowski holds academic positions at the University of Toronto in
the Department of Laboratory Medicine and Pathobiology and the
Department of Surgery and the Florida Atlantic University, the Centre
for Molecular Biology and Biotechnology. Prior to Pivotal, he was
Founder, Chairman, CEO and CSO at SynX Pharma Inc. He has served as
the Chairman of Bio Canada Connect, a Board Member of the Ontario
BIOCouncil and on the Board of Directors for the Canadian Stroke
Network. His scientific resume includes authoring 44 publications and
61 abstracts, holding over 153 patents filed and issued. Dr.
Jackowski received the 1996 MEDEC Award for Medical Achievement for
his invention of the Cardiac STATus(TM) CK-MB/Myoglobin/Troponin Card
Test. He developed and holds the patents on the rapid format
immunoassays measuring cardiac enzymes, in particularly Troponin,
which aids in the early diagnosis of myocardial infarction and is
commercialized worldwide in hospital emergency rooms. Dr. Jackowski
has also served on many federal and provincial governmental
biotechnology committees and is on the Scientific Board of Advisors
for the Innovation Cluster, Trent University. Dr. Jackowski has been
intimately involved in the enforcement of patent claims, patent
litigation and patent interference proceedings. Dr. Jackowski, a
respected cardiovascular biochemist, trained at the Cardiovascular
Research Institute at the University of San Francisco, California and
at the Department of Clinical Biochemistry at the University of
Toronto. Dr. Jackowski has over 30 years experience and extensive
networks in the CVD and central nervous system (CNS) disease markets,
particularly pertaining to the commercialization of diagnostic
products.

About VASCAZEN(R)

VASCAZEN(R) is a prescription only Medical Food specifically
formulated for the dietary management of an Omega-3 deficiency in
cardiovascular patients. VASCAZEN(R) is a >90% pure Omega-3 with a
proprietary 6:1 EPA:DHA fatty acid formulation, protected by a series
of both U.S. and foreign patents. VASCAZEN(R)is the second to market
prescription only Omega-3 therapy available in the U.S. and is
available by prescription nationwide.

About Pivotal Therapeutics Inc.

Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF) (CNSX:
PVO) specialty pharmaceutical company with a focus on cardiovascular
disease and overall health. Pivotal Therapeutics' lead product
VASCAZEN(R) is a prescription only Medical Food formulated to meet
the dietary Omega-3 deficient needs of patients with cardiovascular
disease through elevating Eicosapentaenoic acid (EPA) and
Docosahexaenoic acid (DHA) to levels associated with reduced risk of
cardiovascular complications. OMAZEN[TM] is a prescription grade
Omega-3 providing >90% total Omega-3 in each capsule with a unique
6:1 ratio of EPA:DHA. OMAZEN[TM] is a patented product available for
sale and distribution in Canada.

Disclosure Notice The information contained in this document is as
of May 2, 2013. This press release contains forward-looking
statements. Such forward-looking statements are subject to a number
of risks, assumptions and uncertainties that could cause Pivotal's
actual results to differ materially from those projected in such
forward-looking statements. These statements can be identified by the
use of words such as "will", "anticipate", "estimate", "expect",
"project", "forecast", "intend", "plan", "believe", "project",
"potential", and similar expressions with any discussion of future
operating or financial performance or events. In particular, factors
that could cause actual results to differ materially from those in
forward looking statements include the following: Pivotal's inability
to obtain additional financing on acceptable terms; growth in costs
and expenses; inability to compete with others who provide comparable
products; risk that the Company's products will not gain widespread
market acceptance; risks relating to the Company's ability to
maintain its CSNX listing. Forward-looking statements speak only as
of the date made and are not guarantees of future performance. The
Company undertakes no obligation to publicly update or revise any
forward-looking statements contained in this document as a result of
new information or future events or developments. CNSX has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this information.

SOURCE: Pivotal Therapeutics Inc.

For further information:

Company Contacts:

Rachelle MacSweeney
President and Chief Operating Officer
Phone: +1-905-856-9797
E-Mail: rmacsweeney@pivotaltherapeutics.us

Kristine DiMatteo
Communications and Public Relations Manager
Phone: +1-905-856-9797 ext. 231
E-Mail: kdimatteo@pivotaltherapeutics.us

http://www.pivotaltherapeutics.us

(PVO. PVTTF)

ots Originaltext: Pivotal Therapeutics Inc
Im Internet recherchierbar: http://www.presseportal.de